1 / 21

*C HARITÉ ONKO LOGIE:Clinical studies in GI cancers

Preliminary Results: A randomised, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer - CONKO*-001 -.

aiko
Télécharger la présentation

*C HARITÉ ONKO LOGIE:Clinical studies in GI cancers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preliminary Results:A randomised, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer- CONKO*-001- P. Neuhaus, H. Oettle, S. Post, K. Gellert, K. Ridwelski, H. Schramm, C. Zülke, G. Fahlke, J. Langrehr, L. Roll, H. RiessCharitè - Universitätsmedizin Berlin - Campus Virchow Klinikum;Ruprecht-Karls-Universität, Mannheim; Oskar-Ziethen-Krankenhaus, Berlin; Otto-von-Guericke-Universität, Magdeburg; Wald-Klinikum, Gera; Universität Regensburg, Regensburg; AIO; CAO; Deutsche Krebsgesellschaft e.V. *CHARITÉ ONKOLOGIE:Clinical studies in GI cancers

  2. CONKO-001Rationale • Prognosis in disease free survival with pancreatic cancer is still poor • Median survival after resection is 11 - 25 months • Long term survival (>5 years) is 8 - 21percent Bakkevold (1993); Klinkenbijl (1999); Gastrointestinal Study Group (1985, 1987); Neoptolemos (2004)

  3. CONKO-001 Study Design Resected pancreatic cancer 368 patients Stratification: R; T; N Observation for 6 months Gemcitabine for 6 months Follow up every 8 weeks

  4. CONKO-001 Disease Monitoring Randomisation Ultrasound after week 16 CT Scan after week 32 Ultrasound after week 8 Gem Gem Gem Gem Gem Gem Follow up every 8 weeks Obs Obs Obs Obs Obs Obs 4 weeks 4 weeks 4 weeks 4 weeks 4 weeks 4 weeks CA 19-9 CA 19-9 CA 19-9 CA 19-9 CA 19-9 CA 19-9 CA 19-9 Gem Gemcitabine 1000 mg/m²: d1, 8, 15; q 4 weeks Obs Observation: d1; q 4 weeks

  5. CONKO-001 Endpoints • Primary Endpoint • Disease free survival (DFS) • Secondary Endpoint • Overall survival (OS) • Toxicity

  6. CONKO-001 Entry Criteria • Histologically proven resected pancreatic carcinoma • Standard operation • No measurable disease • No prior chemo- or radiotherapy • No active infection • Karnofsky performance status  50% • Adequate hematologic, renal and hepatic function • CA 19-9, CEA < 2.5 ULN • Start with adjuvant therapy within 6 weeks after resection • Written informed consent

  7. CONKO-001 Statistics • Hypothesis: • Significant increase in disease free survival (DFS) of at least 6 months due to chemotherapy with gemcitabine • Statistics: • Kaplan-Meier estimates und two-tailed log-rank test with significance level of 0.05 and a power of 90% • Sample size: • 368 pts – 184 pts per treatment arm (1:1 ratio) • including an estimated drop out rate of up to 20%

  8. CONKO-001 Recruitment and Analysis • Time of recruitment: 7/98 - 12/04 • Recruited patients: 368 • Recruiting centres: 88 (Germany, Austria) Date of Analysis: March 2005

  9. CONKO-001 Recruitment Patients Patients per month

  10. CONKO-001 Patient Disposition 368 patients enrolled 7/98 - 12/04 186 pts. for Gemcitabine 182 pts. for Observation 177 eligible* pts. (97%) 179 eligible* pts. (96%) * 7 excluded Patients: 4 pts. lost to follow up 1 pt. without histological proven pc 1 pt. with persistent disease after resection 1 pt. with another tumor disease * 5 excluded Patients: 3 pts. lost to follow up 2 pts. with another tumor disease

  11. CONKO-001 Patient Characteristic

  12. CONKO-001 Tumor Characteristic

  13. CONKO-001 Toxicities WHO Grade III+IV

  14. CONKO-001 Toxicities WHO Grade III+IV

  15. CONKO-001 Toxicities WHO Grade III+IV

  16. CONKO-001 Kaplan Meier Disease Free Survival Chemotherapy with gemcitabine median: 14.21 months (95% CI, 12.86; 15.57)41 % patients censored (+) Observation median: 7.46 months (95% CI, 6.80; 8.11)22 % patients censored (+) Log Rank: p=0.001

  17. CONKO-001 Disease Free Survival

  18. CONKO-001 Kaplan Meier Survival Chemotherapy with gemcitabine53 % patients censored (+) Observation45 % patients censored (+)

  19. CONKO-001 Preliminary Data Summary • Toxicity of gemcitabine in adjuvant therapy is low • Treatment with gemcitabine results in an improvement in disease free survival • Favourable overall survival with chemotherapy (no comparative calculations done; 49% of patients censored) • Improved longterm (3- and 5-year) survival expected

  20. CONKO-001 Conclusions • Treatment with gemcitabine in patients with resected pancreatic cancer results in improved disease free survival as compared to observation • Gemcitabine may become the standard of care for adjuvant treatment of pancreatic cancer

  21. CONKO-001 Top recruiting centres • Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum - Germany • Klinikum Mannheim gGmbH, Universitätsklinikum, Fakultät für Klinische Medizin Mannheim - Germany • Paritätisches Krankenhaus Lichtenberg, Oskar-Ziethen-Krankenhaus, Berlin - Germany • Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät - Germany • SRH Wald-Klinikum Gera gGmbH - Germany • Klinikum der Universität Regensburg - Germany • Eberhard-Karls-Universität Tübingen, Universitätsklinikum Tübingen - Germany • Universitätsklinikum Bonn, Medizinische Fakultät der Rheinischen Friedrich-Wilhelms-Universität - Germany • Klinikum Bremen Mitte gGmbH - Germany • Städtisches Klinikum Magdeburg, Standort Altstadt - Germany • Klinikum der Friedrich-Schiller-Universität zu Jena - Germany • Klinikum Nürnberg Nord - Germany • Klinikum und Fachbereich Medizin der Johann-Wolfgang-Goethe Universität Frankfurt am Main - Germany • Praxis Dr. Schlag, Würzburg - Germany • Universitätsklinikum Freiburg - Germany • DRK Krankenhaus Luckenwalde - Germany • Praxis Drs. med. Mayr & Strohbach, Berlin - Germany • Praxis Drs. med. Günther & Sauer, Potsdam - Germany • Praxis Dr. Hauch, Erfurt - Germany • Humaine Klinikum Bad Saarow - Germany • Henriettenstiftung Hannover - Germany • Charité, Universitätsmedizin Berlin, Campus Berlin-Buch - Germany • Diakoniekrankenhaus Rotenburg (Wümme) - Germany • Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH - Austria • Israelitisches Krankenhaus in Hamburg - Germany • Städtisches Krankenhaus Hildesheim GmbH - Germany • Praxis Dr. von Grünhagen, Cottbus - Germany • Städtisches Klinikum Dessau - Germany

More Related